● pepmg Research Desk · Peer-reviewed evidence review
What the research says about Epithalon
A neutral summary of the peer-reviewed literature on Epithalon (Epitalon), a synthetic pineal tetrapeptide studied mainly in animal and cell models of aging, with a small human literature dominated by a single research group. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from a pineal-gland extract and studied mainly in animal and cell models of aging, telomere biology, and the retina [2][8].
- In animal and cell work it has been reported to influence lifespan and tumor development in rodents and to upregulate telomerase and telomere length in cultured human cells [3][5][6].
- The human literature is small and much of it comes from a single research group, so it does not amount to large independent controlled trials [1][2][8].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What Epithalon is
Epithalon, also called Epitalon or the AEDG peptide, is described in the literature as a synthetic tetrapeptide (Ala-Glu-Asp-Gly) designed from the amino-acid composition of Epithalamin, a bovine pineal-gland peptide extract, and studied for geroprotective and neuroendocrine effects [2][8]. It is sold by third-party research-chemical vendors and is offered for laboratory and research use only.
Most of the published Epithalon research is preclinical, carried out in animals and cultured cells; a substantial share of the work, including the human studies, originates from a single line of research (the St. Petersburg pineal-peptide group), which is worth keeping in mind when weighing the literature [1][2][8].
What the research has measured
Limited evidenceIn animal and cell studies, Epithalon has been reported to act as a geroprotector: in mice and rats it was examined for effects on estrous function, chromosome aberrations, lifespan of the longest-lived animals, and spontaneous tumor development [5][6], and it was reported to protect the morphology and bioelectrical activity of the retina in rats with hereditary retinal degeneration [7]. Cell studies have examined its influence on telomerase, reporting dose-dependent telomere-length extension and hTERT upregulation in cultured human cells [3], and its effect on neuronal-differentiation gene expression in human stem cells [4].
The human data are small. A study combining animal and clinical observation reported a positive clinical effect on retinal function in patients with degenerative retinal lesions [1], and review articles from the same research tradition summarize clinical-trial claims of geroprotective activity for the parent extract and the peptide [2][8]. These human reports are limited and largely tied to one research group.
What the trials report on safety and adverse events
Limited evidenceThere is little human safety data on Epithalon to report. Long-term dosing studies describing tolerability have been carried out in mice, where the authors reported geroprotector activity and described long-term administration as safe in that animal model [5]; animal experiments are not designed to establish human safety, tolerability, or adverse-event rates.
There are no large independent controlled trials establishing the safety of Epithalon in the general population, and the human literature is small and concentrated in one research tradition. This is not medical advice; the human safety of Epithalon is not established. Consult a qualified professional and read the studies directly.
How strong is the evidence
Because the Epithalon evidence base is mostly preclinical (animal and cell models) with only small human reports, much of it from a single research group, it is characterized as limited [1][2][8]. "Limited" describes the state of the research, not a judgment of whether Epithalon works or is safe, and it reflects the narrow provenance and small size of the human literature. Animal and cell findings, however interesting, frequently fail to translate to people.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 8
- Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa.
- Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising Properties.
- Epitalon increases telomere length in human cell lines through telomerase activation.
- AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis in human stem cells.
- Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice.
- Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination.
- Effect of epithalon on age-specific changes in the retina in rats with hereditary pigmentary retinal degeneration.
- Peptides and Ageing.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.